Introduction
Use of adenoviral vectors in clinical gene therapy trials continues to accelerate. 1 This is particularly true for the gene therapy of cancer [2] [3] [4] [5] [6] [7] [8] and reflects the diverse tissue tropism and high gene transfer efficiency of E1-deleted adenovirus vectors. 9 Despite widespread interest in the use of adenoviral vectors for the treatment of cancer only two trials has been reported to date. In the first study an adenovector encoding the LacZ reporter gene was injected into lung cancers and issues of safety and transgene expression were addressed. 7, 10 In the second trial an adenovector-expressing p53 was directly injected into head and neck cancers; side-effects were minimal and two of 17 patients exhibited a partial response. 11 In this trial, vector shedding was observed in blood at 30-90 min after injection, but not at 24 h. Furthermore, at doses greater than 5 × 10 9 p.f.u. vector was detected in urine and sputum of patients for up to 17 days after injection.
Systemic delivery of recombinant interleukin-2 (IL-2) to patients is limited by side-effects and the short half-life of the protein. 12 In attempts to overcome these limitations tumor cells transduced ex vivo with retroviruses expressing IL-2 have been utilized in animal models and have been shown to enhance tumor immunotherapy significantly when compared with untransduced cells. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Using direct intra-tumoral administration of an adenoviral vector expressing IL-2, Haddada et al 23 have also demonstrated enhanced tumor cell immunogenicity. Our own pre-clinical studies in a murine model of breast cancer have previously demonstrated that intra-tumoral delivery of the cytokine IL-2 by adenoviral infection results in resolution of tumor both locally and at distant (noninjected) sites. 24, 25 Moreover, animals showing a complete response to this treatment develop protective immunity to rechallenge with parental tumor cells. To begin to explore the utility and safety of adenovector delivery of cytokines in human tumors we therefore conducted a phase 1 trial of an adenovirus expressing human (h)IL-2 (AdCAIL-2) in patients with subcutaneous deposits of metastatic breast cancer or melanoma. 3 AdCAIL-2 is an E1/E3-deleted, replication-deficient recombinant adenovirus derived from serotype 5 (Ad5) which expresses the hIL-2 under the control of the human CMV intermediateearly promoter. Primary endpoints of the study were biologic safety, clinical tolerance and biologic efficacy. Specifically, evidence for adenovector shedding, generation of replication-competent adenovirus, clinical toxicity, persistence of vector DNA in target cells, expression of the IL-2 transgene, secretion of IL-2 protein, changes in tumor histopathology, changes in immune parameters (circulating CD4/CD8 lymphocyte count, serum immunoglobulins, anti-adenovirus IgG, neutralizing antibodies and antinuclear antibodies/ rheumatoid factor) were all explored following vector exposure. Results from a single intra-tumoral injection of AdCAIL-2 at one of seven dose levels (10 7 -10 10 p.f.u.) in 23 patients are reported.
Results

Clinical trial outline
In a phase 1 trial escalating doses of AdCAIL-2 were injected directly into subcutaneous tumor nodules in patients with refractory metastatic breast cancer and melanoma. Details of the trial design have previously been published. 3 In brief, three patients were treated at each dose level with an initial starting dose of 10 7 p.f.u. (approximately 10 9 particles) escalating in half log increments to 10 10 p.f.u. Testing of clinical grade vector stocks before initiation of the trial revealed no RCA in 10 8 p.f.u. of AdCAIL-2 but at least one p.f.u. of RCA in 10 9 replication-defective vector particles. Before injection, patients throat swabs, urine, stool and a baseline tumor biopsy were screened for both RCA and AdCAIL-2 using a bio-assay on 293 and A549 cells and by PCR of whole blood, saliva and the baseline tumor biopsy (see below). At 24 h (last 10 patients) and at 7 days after injection blood, throat swabs, urine and stool were screened by bio-assay and the blood and saliva were screened by PCR. Patients were maintained in isolation for 72 h after injection until PCR testing confirmed absence of viral shedding. In 21 patients a tumor biopsy was obtained from the injection site 7 days after injection and was screened both by bio-assay and by PCR for RCA and AdCAIL-2. In one patient the biopsy was delayed to 14 days to look for duration of vector persistence and in the final patient on trial the biopsy was obtained 2 days after injection to look for IL-2 protein at the time of expected maximal expression.
Patient characteristics and clinical response
Twenty-three patients (eight breast cancer and 15 melanoma) were treated at seven dose levels (Table 1) . No grade 3 or 4 toxicities were observed. Injection was well tolerated with patients complaining of minor discomfort at the site of injection only. Clinical inflammation at the site of injection was frequent at all dose levels (Figures 1 and 2 ) and marked in three patients where clinical suspicion resulted in treatment for cellulitis. Inflammation was apparent by 24 h, maximal at 72 h after injection, and then generally resolved by day 5 to 7 after injection. Although liver toxicity has been suggested in animal models of adenovirus gene delivery, 4 we did not observe any abnormal liver function except in patients with known liver metastases. Three melanoma patients (at dose levels 5 × 10 9 and 10 10 p.f.u.) developed symptoms of fever, malaise and anorexia after injection which resolved within 48 h in each instance.
Two patients with tumor regression at the injection site (one melanoma and one breast cancer) received a second injection on days 20 and 47, respectively. In the first of these patients, re-injected on day 20, fever of 40°C on the evening of the second injection was noted. Otherwise no new side-effects were noted and no further tumor regression was observed in either patient. Two patients treated at low titer (one melanoma and one breast cancer) without response subsequently received a second injection at higher titer on days 15 (10 8.5 followed by 10 9 p.f.u.) and at 8 months (10 7.5 followed by 10 10 p.f.u.), respectively. Neither patient experienced adverse response to the second injection but no tumor regression was noted. In a final patient, the last on trial, a planned series of five injections was conducted on days 1 (10 10 p.f.u.), 4, 8, 12 and 15 (each at 5 × 10 8 p.f.u.). After each of the first three injections clinical inflammation was noted at the injection site. After the fourth and fifth injections the local inflammatory response to injection was diminished. This patient had no local response to treatment and has stable disease in other sites at this time. These patients are all summarized in Table 1 .
Although the trial was phase 1 in nature and not powered to address efficacy, response rates were recorded. Local tumor regression at the site of injection was noted in six patients (24%) (Figure 3 ). However, using standard criteria, no partial or complete systemic responses were documented. Five of the local responses at the site of injection occurred in melanoma patients (five of 15, 33%) and only one of the eight breast cancer patients. Systemic progression was noted in the majority of patients, including the six patients in whom reduction in tumor size at an injection site was documented.
Replication-competent adenovirus is not detected As described above, pre-clinical testing was conducted in which a known dilution of adenovirus serotype 5 (RCA) was plated on 293 and A549 cells. In these experiments this bio-assay detected as few as 10 p.f.u. of E1-containing virus. During the clinical trial 96 pre-injection samples of tumor, stool, saliva and throat swab were processed using this bio-assay and were all negative. Pre-clinical studies using PCR of adenovirus E1 sequences also detected as few as 10 p.f.u. of RCA and less than 10 picograms of RCA DNA. E1 PCR on 72 samples of pre-injection tumor, blood cells or saliva was negative in all instances. ␤-Actin PCR confirmed the integrity of extracted DNA in all cases. For all 24 patients, testing for RCA was again performed at 1 week after injection of AdCAIL-2 on blood cells, urine, stool, throat swab and injected tumor. In the last 11 patients testing was also performed on blood cells, urine, stool and throat swab taken at 24 hours after injection. All 164 samples tested after injection of AdCAIL-2 were negative for RCA both by PCR and by bio-assay. These results document that E1 sequences are rare or nonexistent in the tissues tested in this study and therefore that the potential for complementation of Ad vectors in vivo is minimal. They also suggest that RCA is not generated following injection of AdCAIL-2 and that the minimal level of RCA contamination of vector stocks does not result in shedding of RCA from patients, or that shedding, if present, is below the level of detection of the assays employed. Characteristics of patients are shown including diagnosis, p.f.u. injected, day of biopsy, side-effects, pre-and post-injection biopsies graded for lymphocyte infiltration (scale 1-4) and response NR (no response), LR (local injection site tumor regression only). There were no conventional complete or partial responses.
Adenovirus vector shedding is infrequent
Pre-clinical testing revealed that as few as 10 p.f.u. of AdCAIL-2 could be detected by CPE on 293 cells after 7 days of culture. PCR for the CMV-IL-2 cassette could detect dilutions of a known concentration of AdCAIL-2 down to 1.5 × 10 4 p.f.u. on ethidium gels and 1.5 × 10 3 p.f.u. following Southern transfer of ethidium gels and hybridization with an internal IL-2-specific probe. Sampling was performed on blood, urine, stool, throat swabs and biopsied tumor as for RCA (described above). Only one blood sample was PCR-positive for shed virus 24 h after injection of 10 9.5 p.f.u. AdCAIL-2. No other tissue sample studied contained vector except the injected tumor site (see below). These results indicate that shedding of vector in immunocompetent hosts is minimal.
AdCAIL-2 DNA and hIL-2 mRNA is detected for at least seven days after injection Day 7 tumor biopsies were obtained in 21 patients and a day 14 biopsy in one patient. In 18 of these 22 biopsies (83%) vector DNA was detected by PCR ( Figure 4 ). In the biopsy taken at 14 days, vector-derived DNA, although faint, was still present. RNA was extracted from day 7 tumor biopsies and RT-PCR performed to look for IL-2 mRNA. Sixty-two percent of tested samples contained IL-2 mRNA ( Figure 5 ). Only one of six samples at 10 7 or 10 7.5 p.f.u. was positive while above 10 8 p.f.u. 80% of tumors contained detectable hIL-2 mRNA. The presence of a unique MwoI restriction site in the wild-type, but not the vector-derived IL-2 allowed us to distinguish endogenous IL-2 from vector-derived message ( Figure 6 ). The majority of IL-2 in the tumors 7 days after injection of AdCAIL-2 was vector derived as determined by visual examination of ethidium-stained gels. To corroborate these findings we also used an ELISA to detect IL-2 protein. IL-2 was detected by ELISA at 16 pg/ml in the supernatant of homogenized tumor from a pre-injection biopsy and at 242 pg/ml in a 48-h post-injection tumor biopsy from the same patient. All other patients had tumor biopsies taken on day 7 and no IL-2 was detected 
u. of vector (a) and on day 3 after injection (b).
in any of the tumor homogenate samples by ELISA. This pattern would be consistent with the known expression pattern following infection of tumor cells with an adenoviral vector with maximum transgene expression occurring between 2 and 3 days after infection. IL-2 was not detected in the serum from any patient at 48 h or at 7 days after injection.
Pathology and immunohistochemistry reveal T lymphocyte infiltration and tumor necrosis
The tumor biopsy samples taken 7 days after injection revealed extensive post-injection lymphocyte infiltration ( Figure 7 ) even at the lower dose levels (Table 1) . At higher dose levels the lymphocyte infiltrate was accompanied by tumor necrosis. Necrosis was also visible clinically in some patients. Immunohistochemical studies demonstrated that the infiltrating cells were almost entirely CD3-positive T lymphocytes (Figure 8a ). The majority of the T cells were CD8 positive (Figure 8b ), but scattered CD4 and CD56 positive NK cells were also present. CD20-positive B cells were rare or absent and only occasional histiocytes positive for CD68 were noted in the post-injection biopsies.
Host immune function after injection
Anti-adenovirus IgG and adenovirus neutralizing antibodies were both measured at baseline and at 1 month after injection. All patients had detectable anti-adenovirus IgG antibodies before injection, albeit at relatively low levels. After injection a consistent rise in anti-Ad IgG antibody titer ( Figure 9 ) was noted in all patients and appeared dose-dependent. More than half the patients studied (9 of 16) had no detectable neutralizing antibodies before injection and three of these nine patients had no or minimal rise in neutralizing antibodies after injection ( Figure 10 ). One patient had high levels of neu- tralizing antibodies before injection. A rise in neutralizing antibody titer was observed after injection in 14 of 16 patients and appeared to be dose-dependent. Circulating CD4 and CD8 counts fell significantly from baseline levels in the 24 h following injection of AdCAIL-2 ( Figure 11 ) before returning to baseline by 7 days after injection, a finding which might suggest recruitment of circulating T lymphocytes into the tumor bed. In other assays of immune function no consistent changes in serum immunoglobulin levels or in circulating monocyte or eosinophil counts were noted among the trial population after injection although six of 22 patients had at least one episode of eosinophil leukocytosis (Ͼ0.4 × 10 9 /l) detected during the follow-up screening over 1 month (Figure 12 ). Six patients also displayed at least one episode of monocytosis (Ͼ0.8 × 10 9 /l), but the monocytosis and eosinophilia was entirely asymptomatic. No elevations in monocyte or eosinophil count were sustained.
To exclude the generation of autoantibody formation, nine patients were tested for the presence of antinuclear antibodies and rheumatoid factor before and after injection. ANA assays were all negative at both time-points. Seven patients had rheumatoid factor measured before and after injection. Three patients were weakly positive before injection, two of these tested negative after injection. One of the four patients testing negative before injection became weakly positive after injection.
Discussion
The results of this phase 1 trial document a number of important observations. First, with regard to the safety of adenovectors for clinical use, no evidence for the appearance of replication-competent adenovirus was noted in 164 biologic specimens processed after injection of AdCAIL-2 using highly sensitive PCR assays or by culture on A549 cells. Indeed in contrast to reports from patients with cystic fibrosis, 26, 27 no evidence for the presence of RCA infection or Ad5 E1 sequences was noted by PCR of DNA from 250 samples of blood, saliva or tumor taken either before or after injection of AdCAIL-2. We can conclude that endogenous Ad5 E1 DNA sequences are uncommon in the tissues studied in this trial population and that the potential for in vivo endogenous complementation of E1-defective adenoviruses is therefore very low. Second, we can conclude that vector shedding into saliva, blood, urine and stool is only rarely present at 24 h or 1 week after injection when assessed by PCR with a sensitivity of 1500 p.f.u. of vector. Furthermore, using a 293 cell based bio-assay capable of detecting as few as 10 p.f.u. of vector, no shedding was documented in any patient treated. Thus all available data from this trial indicate that shedding of AdCAIL-2 in body fluids was negligible. Consistent with our findings a recently reported trial using an adenovirus expressing p53, noted that vector was detected in blood at 30-90 min after injection but not at 24 h. At titers above 3 × 10 10 p.f.u. the Adp53 vector was detected in urine and saliva for up to 17 days. Our trial closed at 10 10 p.f.u. without evidence of shedding which may have been detected at higher dose levels. Indeed in other studies of AdCAIL-2 we have subsequently noted widespread vector dissemination at autopsy (submitted for publication).
Before beginning this trial, we expected that the AdCAIL-2 vector would be rapidly cleared from infected cells by pre-exisiting anti-adenoviral antibodies. In fact this is clearly not the case as we documented an unanticipated persistence of the vector in day 7 or 14 tumor biopsies from 18 of 22 patients (83%). This finding is in agreement with those of other groups reporting recent phase 1 studies of Ad vectors 7, 10, 27, 28 and suggests that previous immunity to adenovirus infection does not preclude prolonged persistence of adenovectors after a single injection. Nevertheless, analysis of post-injection serum samples demonstrated generation of anti-adenovirus IgG in all of the 16 patients studied and of adenovirus neutralizing antibodies in 13 of the 16 patients. Nine of 16 patients before injection, but only three of the 16 patients studied 1 month after injection had no or minimal levels of detectable neutralizing antibodies. The rapid development of IgG and adenovirus neutralizingantibodies within 1 month of injection is in keeping with the results of other groups 7, 10, 27, 28 and suggests that readministration of first generation E1-deleted adenovectors may be associated with rapid clearance of vector and dimished transgene expression. 28, 29 Indeed in a single patient who received five injections of AdCAIL-2, inflammation followed the first three injections, but not the fourth or fifth, suggesting that anti-adenoviral
Figure 4 Detection of AdCAIL-2 in tumor biopsies. Biopsies before and after injection of AdCAIL-2 were PCR amplified using primers specific for AdCAIL-2 (5Ј Human CMV promoter, 3Ј human interleukin-2). Pre-injection biopsy samples are shown in lanes A, C, E, G and post-injection biopsies in lanes B, D, F and H. Lane I is a positive control using the vector. In all four patients shown in this Figure, the vector was easily detected in the post-injection biopsies (top). All samples contained DNA as assessed by ␤-actin PCR ( bottom panel).
neutralizing antibodies prevented transgene expression after the third injection. Serial tumor biopsies were not available to confirm this clinical observation at the molecular level. It is perhaps relevant to note that in a murine model previous adenovirus exposure did reduce adenoviral transgene expression at the site of injection 2.4-fold, but did not eradicate the development of antitumor immunity and did limit viral spread systemically. 30 In human trials in cystic fibrosis, re-administration of vector does appear to be associated with diminished transgene expression with serial injections. 28 In 62% of patients on our trial and in 80% of patients treated with greater than 5 × 10 8 p.f.u. of AdCAIL-2, the local expression of vector-derived IL-2 mRNA was detected for at least 7 days after injection. In one biospy taken at 14 days, the transgene was still weakly expressed. This molecular evidence for adenoviral transgene expression is supported by the pathologic evidence of biologic activity as demonstrated by the post-injection tumor necrosis and florid T cell infiltration. Despite evidence for IL-2 expression at the molecular level, homogenates of day 7 tumor biopsies failed to detect IL-2 protein by ELISA. IL-2 was however detected at 48 h after injection when Ad vector expression was likely maximal at a level 15 times higher than that detected in the tumor at baseline.
Patient immune parameters studied in this trial demonstrated an in vivo drop of CD4
+ and CD8 + T cells in the circulation accompanied by an increase in lymphocyte infiltrates in tumor beds and clinical inflammation at the site of injection. The drop in circulating T lymphocyte counts is unexplained but might suggest recruitment of T cells into the injected tumor bed. We believe that these observations most likely reflect vector IL-2 transgene expression, rather than an immune response to adenoviral proteins as other clinical trials of first generation adenoviral vectors have failed to note lymphocyte infiltration when the Ad vectors have expressed LacZ, or p53. 7, 11, 31 Nevertheless, trials in cystic fibrosis patients have demonstrated an inflammatory response to Ad5 vectors expressing CFTR and since no control vectors have been used in a clinical setting it is impossible to differentiate further the contributions of Ad5 proteins and IL-2 to the host immune response in our trial. Further interpretation of our results must therefore be extrapolated from murine studies. In our pre-clinical murine models of adenovector-mediated cytokine gene delivery a slight delay in tumor growth is observed after injection of adenovector alone but significant tumor regression is only observed when the adenovector delivers a cytokine or costimulatory molecule into the tumor. 23, 32, 33 Furthermore, a cytotoxic T cell response to tumor-specific antigens is evident only in responding animals injected with the adenovirus encoding cytokine. The results of these murine experiments taken together with the results of other human trials support the contribution of adeno-
Figure 5 IL-2 expression in tumors before and after injection of AdCAIL-2. RT-PCR was used to look for expression of IL-2 in the injected tumors both before and after injection of AdCAIL-2. Pre-and post-injection biopsies from two patients are shown in lanes A and C and lanes E and G, respectively. Lanes B, D, F and H are negative control lanes and lane I is a positive control from 293 cells infected with AdCAIL-2. PCR for IL-2 is shown in the top panel while ␤-actin PCR for cDNA integrity is shown in the lower panel. In one patient, lanes A and C, no IL-2 is detected either before or after injection. In the second patient, lanes E and G, IL-2 is detected only after injection.
Figure 6 Interleukin-2 in tumors is vector-derived. The naturally occurring hIL-2 gene contains a MwoI restriction enzyme site at bp 163 that the vector-derived hIL-2 gene lacks because of a silent T to G substitution. RT-PCR products from tumor biopsies were therefore digested with MwoI. Lanes (left to right): M is size marker VI; lane 1 is tumor after injection; lane 2 is normal donor pHA activated T lymphocytes; lane 3 is recombinant IL-2 plasmid. Thus, while PCR-amplified IL-2 from normal donor T lymphocytes is digested by MwoI the majority of hIL-2 cDNA derived from the tumor and all of the plasmid DNA control is undigested confirming that IL-2 present in the tumor is predominantly derived from the adenovirus.
vector-derived IL-2 to the lymphocyte infiltration and clinical inflammation observed in this study.
No evidence for autoimmune response was noted; at least as defined by the presence of antinuclear antibodies or rheumatoid factor. Similarly, no clinical symptoms compatible with autoimmune disease were seen and serum immunoglobulin levels did not significantly change after injection. These findings suggest that the inevitable infection of host fibroblasts and connective tissues within the tumor and the resultant expression of IL-2 by these cells is insufficient to generate clinically significant auto-immunity despite the theoretical risk that this may occur.
These data together demonstrate that AdCAIL-2 injection into human tumors in vivo may result in local transgene expression and activity. The biologic activity of a single injection of the vector translates into clinical inflammation in a majority and reduction in injection site tumor size in a minority of patients. These effects appear to be mediated predominantly by a CD3 + CD8 + effector T cell population. The results of this trial encourage further exploration of AdCAIL-2 and other adenovector delivered cytokines in clinical tumor immunotherapy. Potential approaches for future trials include using repeated injections, higher dose levels or combination with other immune stimulatory cytokines. 34 It will be important in 
u. of AdCAIL-2 (b) breast cancer tumor biopsies show a dramatic increase in infiltrating lymphocytes (×80).
these new trials to document the presence or absence of a CTL response to unmodified tumor cells and to examine further the nature of the immune responses generated by adenovector administration. Maximal benefit may result from treatment of patients with minimal tumor burden.
The results of this phase 1 trial further demonstrate that AdCAIL-2 is safe and relatively non-toxic. No evidence for significant vector dissemination, shedding or generation of replication-competent adenovirus was seen. Adenovector delivered transgene was expressed for at least 7 days after injection and was biologically active, despite which side-effects were uncommon and when apparent were mild. Further studies with this AdCAIL-2 vector and other adenovectors expressing cytokines for the immunotherapy of cancer 33 are planned.
Materials and methods
Bio-assay for virus dissemination
To detect both replication-competent adenovirus (RCA) or AdCAIL-2 dissemination, biologic samples (see below) were inoculated onto 293 cells (ATCC CRL-1573) permissive for the culture of human Ad E1-deleted vectors or on to A549 cells (ATCC CCL-185) which efficiently replicate non-E1-deficient human adenoviruses and cultured for 7 days. Evidence for virus was detected by cytopathic effect (CPE) and by immunofluorescence staining for adenoviral coat proteins using a murine monoclonal anti-adenovirus (Ad) antibody (Bartels adenovirus monoclonal antibody reagent; Bartels, Issaquah, WA, USA).
To establish the sensitivity of these assays 293 and A549 cells were first grown to 100% confluence in 96-well plates using minimal essential medium (MEM) (Gibco, Burlington, Ontario, Canada) supplemented with 2% heat-inactivated fetal calf serum (FCS) (Sigma, St Louis, MO, USA), 1% antibiotic-antimycotic (PSF) (Gibco), and 1% l-glutamine (Gibco). The medium was removed and virus dilutions (10 −1 to 10 −10 in 50 l of MEM and 1% PSF) of AdCAIL-2 and wild-type Ad5 stock strains from the Toronto Hospital Virology Laboratory were added in triplicate. Negative control wells received MEM and 1% PSF. Plates were spun at 700 g for 60 min to enhance infection. After centrifugation, 200 l of maintenance medium (MEM, 2% FCS, 1% PSF) was added to each well. The tissue culture infective dose 50% (TCID 50 ) of Ad5 and AdCAIL-2 were assessed at day 7 using CPE as an endpoint. When a clinical grade stock of AdCAIL-2 at a known titer of 2 × 10 8 p.f.u. /ml was serially diluted and inoculated on 293 cells, the assay was sufficiently sensitive to detect as few 10 p.f.u. of vector.
To confirm that CPE resulted from adenovirus encoded proteins, the infected 293 cells were then fixed by removing supernatant and adding cold acetone for 10 min. The cells were then washed three times with PBS and blocked for 30 min with 2% FCS in PBS at room temperature (RT). After removing excess buffer, cells were incubated with 30 l of the murine monoclonal anti-Ad antibody at 37°C for 20 min. After washing once with PBS the anti-Ad antibody was detected using 30 l of goat anti-mouse FITC IgG F(abЈ) 2 antibody (Bartels) diluted in PBS. After incu- bation for 30 min at RT, the cells were washed three times with PBS, blotted, mounted using glycerol and PBS and examined for immunofluorescence by microscopy. To confirm that the assay was as sensitive in a clinical setting, multiple specimens of stool and bronchoalveolar lavage fluid washings were spiked with AdCAIL-2 and wild-type Ad 5. AdCAIL-2 was consistently detected and identified on the basis of its differential growth in 293, but not A549 cells. In contrast, Ad 5 (wild-type Ad) grew in both 293 and A549 cells. The failure of AdCAIL-2 to replicate on A549 cells allowed vector to be distinguished from RCA. Sensitivity remained high using these clinicals samples.
PCR-based detection of RCA and AdCAIL-2 PCR-based detection of AdCAIL-2 was based on targeting a 487 bp sequence spanning the CMV promoter and the IL-2 portion of the IL-2 expression cassette (CMV promoter, sense 5Ј-TTGGCAGTACATCAATGGGCG TGG and antisense of the IL-2 gene 5Ј-TGAG CATCCTGGTGAGTTTGGG). DNA was isolated from the clinical samples using the Easy DNA Isolation Kit Protocol 3 (Invitrogen, St Louis, MO, USA). As controls a mock DNA extraction was undertaken at the same time as clinical sample handling and was similarly subjected to PCR amplification. PCR was conducted on 1 g total cellular DNA with 200 ng of each primer, 4 l of 2.5 mm of each of the DNTPs, 2.5 l of 100% DMSO, 1.25 l of 1 m KCl, 5 l of 10 × PCR buffer and 2.5 U Taq DNA Polymerase (Boehringer-Mannheim, Indianapolis, IN, USA) in a total volume of 50 l. PCR conditions were as follows: denaturation at 95°C for 5 min, 30 cycles of 94°C for 15 s, 57°C for 15 s and 72°C for 1 min, followed by a 10-min final extension at 72°C. The resulting PCR products were analyzed on a 1% agarose gel stained with ethidium bromide. In some experiments the PCR gel was blotted and probed with an internal IL-2 probe. Using serial dilutions of clinical stock of AdCAIL-2, this PCRbased assay was capable of detecting 1.5 × 10 4 p.f.u. of AdCAIL-2 on ethidium gels and 1.5 × 10 3 p.f.u. by Southern transfer and blotting of the PCR product.
To detect RCA, primers spanning the deleted Ad5E1 region were used (5ЈTTATCTGCCACGGAGGTGT3Ј and 5ЈCGGCGAGCGCCTTCTGGCGG3Ј). PCR products were run on ethidium gels and after Southern transfer were detected with radiolabelled internal probes. This PCR assay could detect as few as 10 p.f.u. of wild-type adenovirus.
Interleukin-2 expression IL-2 was detected in serum and in the supernatant of homogenized tumor biopsies using a commercial Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA). Samples were run as single observations only.
By reverse-transcriptase PCR analysis, tumor cells were examined for hIL-2 mRNA. RNA was extracted (Qiagen, Chatsworth, CA, USA) from tumor biopsies and oligo-dT reverse transcribed. Primers annealing to IL-2 cDNA were IL2F1 5ЈGCATTGCACTAAGTCTTGCAC TTG3Ј and IL2B5 5ЈTTTAGCACTTCCTCCAGAGG TTTG 3Ј. After a 5-min 95°C denaturation step, PCR was performed for 35 cycles at 94°C × 1 min 53°C × 1 min, 72°C × 2 min with a 10-min extension at 72°C. PCR products were detected on ethidium gels. The naturally occurring hIL-2 gene contains a MwoI restriction enzyme site at bp 163 that the vector derived hIL-2 gene lacks because of a silent guanine to thymidine substitution. Thus while PCR amplified IL-2 from normal donor T lymphocytes is digested by MwoI the hIL-2 cDNA derived from the tumor and plasmid DNA control is not cut, confirming that IL-2 present in the tumor is primarily derived from the adenovirus.
Anti-adenovirus IgG and neutralizing antibody titers
Baseline serum samples and samples collected 1 month after injection were analyzed for anti-adenovirus antibody titer. Serial five-fold dilutions of each serum sample were prepared at dilutions of 1:50, 1:250, 1:1250, 1:6250. As controls, canine serum was utilized to set a background baseline. An ELISA was performed using plates coated with lysates of Hela cells infected with wild-type Ad5 virus and blocked by 1% albumin. Detection was with a 1:10 000 dilution of biotin-conjugated goat antihuman antibody (Sigma). An OD reading of 0.12 was designated as one unit of activity. Regression analysis was used to determine the dilution that each sample required, to reach this OD reading. This dilution was then converted into units. The background OD reading for this assay was 0.07. Any sample containing units of activity greater than 6000 is saturated and therefore not accurate.
To measure neutralizing antibodies Hela cells in complete F-11 medium were seeded in 24-well plates at 2 × 10 5 cells per well and cultured for 6 h. Serial five-fold dilutions of serum were prepared with culture medium. An aliquot of 100 l of diluted serum was mixed with a 100 l aliqout of AdLacZ at 6.5 × 10 6 p.f.u./ml in medium and incubated with the Hela cells at 37°C for 1 h. Complete medium (1 ml) was added and cells were cultured for a further 24 h. Cells in each well were then lysed by the addition of 100 l of 250 mm tris (pH 7.8), 0.5% NP-40 and incubated on ice for 20 min. An 875 l aliqout of 10 mm KCl, 1 mm MgSO 4 , 50 mm ␤-mercaptoethanol in 100 mm sodium phosphate buffer (pH 7.5) was added to each well and the plates were incubated at 37°C for 5 min. A 330-l aliquot of the substrate solution (4 mg/ml O-nitrophenol-␤-d-galactopyranoside) (Sigma, Oakville, Ontario, Canada) in 100 mm sodium phosphate buffer, pH 7.5), was then added to each well and incubated at 37°C for 1 h. The reaction was terminated by the addition of 430 l of 1 m Na 2 CO 3 and the optical density of the solution in each well was measured at 450 nm. The relative absorbance for each dilution of anti-serum is presented as the number of dilutions which still resulted in 50% (before injection) or 100% (after injection) neutralization when compared with the absorbance produced using a corresponding dilution of control serum (serum from adenovirus naive mice).
Pathology and immunohistochemistry
Pre-and 7-day post-injection biopsies were fixed in neutral buffered formalin and processsed routinely for embedding in paraffin wax. Standard pathology assessment was carried out on slides stained with hematoxylin and eosin (H&E). Immunoperoxidase analyses were carried out on paraffin sections using a standard streptavidin-biotin technique with microwave antigen recovery and diaminobenzidine as chromogen. The primary antibody reagents used were rabbit polyclonal anti-human CD3, and monoclonal antibodies anti-CD4 (clone OPD4), anti-CD68 (clone PG-M1), anti-CD20 (clone L26) (all from Dako, Carpenteria, CA, USA); anti-CD8 (clone 4B11) (Novocastra Laboratories, Newcastle-upon-Tyne, UK); and anti-CD56 (clone 123C3) (Zymed Laboratories, San Francisco, CA, USA). Secondary antibody alone was used as a negative control.
